A New Era for Sickle Cell Disease, Acute Porphyria, and More

By Basem M. William, MD On Monday, the Director of the Division of Hematology Products in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA), Ann Farrell, MD, chaired the two special ASH-FDA Joint Symposia focusing on new...

Presidential Symposium: Big Ideas for Big Data

By Ahmar U. Zaidi, MD “In God we trust. All others must bring data.” The amount of data generated from the dawn of humanity until 2003 was 5 exabytes. Since then, 5 exabytes of data are created every two days. There is no doubt that our ability to collect and store...

Best Donor Choice: It’s in the Eye of the Beholder!

By Basem M. William, MD One of the major leaps in hematopoietic stem cell transplantation (HSCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to approximately 75 percent of patients who do...

Mission (Im)Possible

By Binod Dhakal, MD, MS The year 1982 heralds the discovery of the first mutated genes to be identified in cancer, RAS. The three RAS genes — KRAS, NRAS, and HRAS — still constitute the most frequently mutated oncogene family in human cancers. However, despite more...

Lymphoma Roundup: Verdict on This Year’s Annual Meeting

By Basem M. William, MD Since Thomas Hodgkin’s initial characterization of lymphomas in 1832 and the first administration of mustard to a patient with lymphoma 100 years later amid the secrecy of a World War II gas program, much has changed. Multiple recurrent themes...